Long-term prophylaxis in hereditary angioedema management: Current practices in France and unmet needs

Author:

Bouillet Laurence1,Fain Olivier2,Armengol Guillaume3,Aubineau Magali4,Blanchard-Delaunay Claire5,Dalmas Marie-Caroline6,De Moreuil Claire7,Du Thanh Aurélie8,Gobert Delphine2,Guez Stéphane9,Hoarau Cyrille10,Jaussaud Roland11,Jeandel Pierre-Yves12,Maillard Hervé13,Marmion Nicolas14,Masseau Agathe15,Menetrey Céline16,Ollivier Yann17,Pelletier Fabien18,Plu-Bureau Geneviève19,Sailler Laurent20,Vincent Denis21,Bouquillon Benoit22,Verdier Edouard22,Clerson Pierre23,Boccon-Gibod Isabelle24,Launay David25

Affiliation:

1. From the National Reference Center for Angioedema (CREAK), Department of Internal Medicine, Grenoble Alpes University, Laboratoire T-RAIG, UMR 5525 TIMC-IMAG (UGA-CNRS), Grenoble, France;

2. Department of Internal Medicine, Sorbonne University, AP-HP, Saint Antoine Hospital, Paris, France;

3. Department of Internal Medicine, Rouen University Hospital, Rouen, France;

4. Department of Internal Medicine, Hospices Civils de Lyon, Edouard Herriot Hospital, France;

5. Department of Internal Medicine, Niort Hospital Center, France;

6. Department of Internal Medicine, Hautepierre Hospital, Strasbourg University Hospital, France;

7. Department of Internal Medicine, La Cavale Blanche University Hospital, Brest, France;

8. Department of Dermatology, University Montpellier, Montpellier, France;

9. Allergy Diseases Unit, Internal Medicine and Post-Emergency, GH Pellegrin, Bordeaux University Hospital, Bordeaux, France;

10. Transversal Unit of Allergology and Clinical Immunology, Medicine Department, Tours Regional University Hospital, Tours University, France;

11. Department of Internal Medicine and Clinical Immunology, Lorraine University, CHRU-Nancy, Nancy, France;

12. Department of Internal Medicine, Nice University Hospital Center, Côte d'Azur University, Nice, France;

13. Dermatology Department, Le Mans Regional Hospital, Le Mans, France;

14. Department of Medicine, Saint Louis University Hospital, Saint Pierre, Réunion;

15. Department of Internal Medicine, Nantes University Hospital, Nantes, France;

16. Limoges University Hospital, Limoges, France;

17. Department of Immuno-Allergology, Caen University Hospital, Caen, France;

18. Department of Internal Medicine, Besancon University Hospital, Besancon, France;

19. Department of Gynecology Obstetrics and Reproductive Medicine, Cochin University Hospital, Paris, France;

20. Internal Medicine, University Hospital Center Toulouse, Toulouse, France;

21. Department of Internal Medicine, Nîmes University Hospital, Nîmes, France;

22. Carely, Lille, France;

23. Soladis Clinical Studies, Roubaix, France;

24. Department of Internal Medicine, CREAK, ACARE Center of Excellence, Grenoble Alpes University Hospital, France, and

25. Department of Internal Medicine and Clinical Immunology, Lille University, Inserm, Lille University Hospital, CREAK, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France

Abstract

Background: Hereditary angioedema (HAE) is characterized by unpredictable and potentially life-threatening attacks of cutaneous and submucosal swelling. Over the past decade, new agents, based on a better understanding of the underlying biologic mechanisms of HAE, have changed the face of long-term prophylaxis (LTP). Objective: The objective was to describe current practices and unmet needs with regard to LTP for HAE in expert centers in France. Methods: The study was conducted in France in 2020. Based on their experience with patients with HAE who had visited their center at least once in the past 3 years, physicians from 25 centers who are expert in the management of HAE were requested to fill in a questionnaire that encapsulated their active patient list, criteria for prescribing LTP, and medications used. They were asked about potential unmet needs with currently available therapies. They were asked to express their expectations with regard to the future of HAE management. Results: Analysis was restricted to 20 centers that had an active patient file and agreed to participate. There were 714 patients with C1 inhibitor (C1-INH) deficiency, of whom 423 (59.2%) were treated with LTP. Altered quality of life triggered the decision to start LTP, as did the frequency and severity of attacks. Ongoing LTP included androgens (28.4%), progestins (25.8%), lanadelumab (25.3%), tranexamic acid (14.2%), intravenous C1-INHs (5.6%), and recombinant C1-INH (0.7%). Twenty-nine percent of the patents with LTP were considered to still have unmet needs. Physicians' concerns varied among therapies: poor tolerability for androgens and progestins, a lack of efficacy for tranexamic acid and progestins, dosage form, and high costs for C1-INHs and lanadelumab. Physicians' expectations encompassed more-efficacious and better-tolerated medications, easier treatment administration for the sake of improved quality of life of patients, and less-expensive therapies. Conclusion: Despite the recent enrichment of the therapeutic armamentarium for LTP, physicians still expressed unmet needs with currently available therapies.

Publisher

Oceanside Publications Inc.

Subject

Pulmonary and Respiratory Medicine,General Medicine,Immunology and Allergy

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3